{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Objectives', 'Endpoints', 'Summary of frequency and dose of IV', 'iron', 'To compare daprodustat to placebo on', 'Estimated Glomerular Filtration Rate', 'renal function', '(eGFR) observed and change from', 'baseline', 'Serum creatinine observed and change', 'from baseline', 'N (%) transitioning to dialysis', 'Evaluate the dose adjustment schemes', 'Assigned dose by visit', 'Most recent dose prior to Week 24,', 'Week 28 and End of Treatment', 'Maximum achieved dose', 'Number (%) of participants with 0, 1, 2 or', '>2 dose adjustment', 'Mean number of dose adjustments', 'Time dose held for Hgb>13 g/dL', 'To compare daprodustat to placebo on', 'N (%) of subjects who had no change,', 'BP medication changes', 'an increase or a decrease in the number', 'of BP medications from baseline to week', '28 or final visit for non-completers', 'To compare daprodustat to placebo on', 'N(%) of participants within each PGI-C', 'the severity and change in symptoms', 'symptom change.', 'To compare daprodustat to placebo for', 'Change in percent and mean number of', 'improving physical activity (actigraphy)', 'hours of daily activity from baseline.', 'Change in percent sleep efficiency from', 'baseline.', '5.', 'STUDY DESIGN', '5.1.', 'Overall Design', 'This is a 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-', 'center Phase 3 study in participants with anemia associated with chronic kidney disease', '(CKD) who are not on dialysis. This study will enroll anemic participants who have a', 'HemoCue Hgb 8.5 to 10.0 g/dL, inclusive. These participants will have limited history of', 'IV iron and be rhEPO na\u00efve prior to screening and randomization.', 'This study includes a 4-week screening period, a 28-week treatment period, and a 4-week', 'follow-up period (Figure 1).', '36']['2016N298481_0', 'CONFIDENTIAL', '205270', 'The total duration of study participation for each participant will be approximately 36', 'weeks.', 'Participants will be randomized 1:1 to receive either daprodustat or matching placebo', 'tablets. Participants will not be provided with the results of their HemoCue Hgb', 'assessment during their participation in the study.', 'Daprodustat and placebo doses for participants will be titrated based upon HemoCue', 'Hgb. Dose modifications for these participants will follow a protocol-specified dose', 'adjustment algorithm to achieve and maintain Hgb within the target range of 11.0 to 12.0', 'g/dL, inclusive. Dose changes will be made programmatically in a blinded fashion by the', 'IRT system in order to ensure that investigators and participants stay blinded to the study', 'treatment and the dose adjustments.', 'A rescue algorithm is provided to minimize participants having an inadequate response to', 'the treatment for their anemia for an extended period of time and to enable rescue therapy', 'to be provided to the participants based on local clinical practice. (Section 7.7.2)', 'Figure 1', 'Study Schematic', 'Treatment Period (28 Wks)', 'Screening', 'Daprodustat', 'Follow-up', 'Period', 'Visit', 'Achieve and Maintain Hgb between 11 to 12 g/dL', 'Week -4 &', 'Placebo', '4 wks after', 'Week -2', 'Last Dose', 'N=600 (1:1 randomization)', 'End of Treatment', 'Start of Treatment', 'Week 28', 'Randomization (Day 1)', '5.2.', 'Number of Participants', 'Approximately 1200 participants with anemia associated with CKD who are not on', 'dialysis will be screened to achieve approximately 600 randomized and to target', 'approximately 540 evaluable participants for an estimated total of 270 evaluable', 'participants with a 1:1 randomization per study treatment group.', '5.3.', 'Participant and Study Completion', 'A participant is considered to have completed the study if he/she has completed all', 'phases of the study including the Follow-up visit, which takes place 4 weeks after the end', 'of study treatment.', 'The end of the study is defined as the date of the last visit of the last participant in the', 'study or the last scheduled procedure shown in Table 1 of Schedule of Activities (SoA).', '37']\n\n###\n\n", "completion": "END"}